Abstract
Current management of intraductal papillary mucinous neoplasm (IPMN) according to recently published International Consensus Guidelines depends upon distinguishing it from mucinous cystic neoplasms (MCNs). We have previously shown that prostaglandin E2 (PGE2) is increased in pancreatic cancer tissue over normal controls. Thus, we hypothesized that PGE2 level in pancreatic fluid differentiates IPMN and MCN and is a biomarker of IPMN dysplasia. Pancreatic fluid was collected in 65 patients at the time of endoscopy (EUS or ERCP) or operation (OR) and analyzed by PGE2 enzyme-linked immunosorbent assay (ELISA). PGE2 level was correlated with surgical pathologic diagnosis and dysplastic stage. Mean PGE2 level (pg/μl) in IPMNs (2.2 ± 0.6) was greater than in MCNs (0.2 ± 0.1) (p < 0.05). Mean PGE2 level of IPMN by dysplastic stage was 0.1±0.01 (low grade), 1.2±0.6 (medium grade), 4.4±0.9 (high grade), and 5.0±2.3 (invasive). Among invasive IPMN, PGE2 level dropped in advanced cases with pancreatic ductal obstruction by tumor (0.3 ± 0) vs non-obstructed (8.6 ± 2.9). PGE2 level may help in distinguishing IPMN from MCN in patients with known mucinous lesions. PGE2 level may also be an indicator of malignant progression of IPMN before ductal obstruction by tumor. Prospective evaluation will be necessary to evaluate the clinical role of PGE2 level in pancreatic fluid.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
